

Lulizumab pegol

Cat. No.:	HY-P99717
CAS No.:	1421830-13-8
Target:	CD28
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the research of kidney transplantation and autoimmunity disease ^[1] .
In Vitro	BMS-931699 shows a K_D value of 0.41 nM for T-cell proliferation by Biacore ^[1] . BMS-931699 shows EC_{50} values of 2.9 and 4.4 nM for T-cell proliferation driven by mixed lymphocyte reaction (MLR) assay and CD28 receptor occupancy (RO) in whole blood ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yang Z, et al. Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699. J Pharmacol Exp Ther. 2015 Dec;355(3):506-15.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA